Medshine Discovery Inc.

Shanghai United Imaging Healthcare Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

China Resources Pharmaceutical Holdings Company Limited

Helioeast Science & Technology Co., Ltd.

Jumbo Drug Bank Co., Ltd.

Guizhou Inochini Technology Co., Ltd

Helioeast Pharmaceutical Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Lele Zhao

Shuhui Chen

Lingyun Wu

Jian Li

Zhaoguo Chen

Jianjun Sun

Fang Liu

XiaWei Wei

Peng Yang

Xu You

Peng Zhang

Charles Z Ding

Guoping Hu

Lihong Hu

Jian Xu

Weiguo Zhang

Jun Zhao

Yuan Zheng

Chen Zhang

Yuanshan Yao

Xile Liu

Ning Zhao

Xiawei Wei

Cailin Wang

Wei Zheng

Wei Pan

Ning Jiang

Zhen Zhan

Xinming Du

Li Zhang

Disclosed are pyrrolotriazine compounds which act as a mitogen-activated protein kinase interacting kinase (MNK) inhibitor, and the use thereof in the preparation of a mitogen-activated protein kinase interacting kinase inhibitor drug. Specifically disclosed are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof.

Pyrrolotriazine compounds acting as MNK inhibitor

Disclosed are an acetophenone oxime compound and a preparation method therefor, and specifically disclosed are a compound as shown in formula (II) and a pharmaceutically acceptable salt thereof.

Acetophenone oxime compound and application thereof

Provided are a compound III serving as an LSD1 inhibitor and a crystal form thereof, as well as use of the compound and the crystal form thereof in preparation of a medicament for treating an LSD1 related disease.

Salt of LSD1 inhibitor and a polymorph thereof

The present disclosure provides a system for SMS MRI. During each of a plurality of frames, the system may cause an MRI scanner to apply a plurality of PE steps to each of a plurality of slice locations of a subject to acquire echo signals. A phase modulation magnetic field gradient may be applied during each of at least some of the PE steps in the frame. For each frame, the system may reconstruct an aliasing image representative of the slice locations in the frame based on the corresponding echo signals. The system may also generate a plurality of reference slice images based on the aliasing images. The system may further reconstruct at least one slice image based on the aliasing images and the reference slice images. Each of the slice image may be representative of one of the slice locations in one of the frames.

Systems and methods for simultaneous multi-slice magnetic resonance imaging

Disclosed are a series of benzo 2-azaspiro[4.4]nonane compounds, and specifically disclosed are a compound as represented by formula (P) or a pharmaceutically acceptable salt thereof.

Benzo 2-azaspiro[4.4]nonane compound and use thereof

Disclosed are a class of pyrazole compounds and applications thereof in the preparation of a medicament for treating related diseases. Specifically, related are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof. 

Pyrazole compounds as LSD1 inhibitors and applications thereof

A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease. 

LSD1 inhibitor and preparation method and application thereof

Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof. 

Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor

Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof. 

Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity

Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.

Dimethylphosphine oxide compound

Growing community of inventors

Shanghai, China

Lele Zhao